A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants with Neovascular Age-related Macular Degeneration
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Chengdu Origen Biotechnology Co., Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT06825858
Safety and Tolerability of KH658 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Chengdu Origen Biotechnology Co., Ltd.
- Target Recruit Count
- 44
- Registration Number
- NCT06458595
- Locations
- 🇨🇳
Tianjin Medical University General Hospital, Tianjin, China
Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Chengdu Origen Biotechnology Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT05672121
- Locations
- 🇨🇳
Beijing Tongren Hospital, Capital Medical University, Beijing, China
Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
- First Posted Date
- 2022-12-20
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Chengdu Origen Biotechnology Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT05657301
- Locations
- 🇺🇸
Kanghong Investigative Site, Dallas, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath